Skip to main content
NYSE:PKI

PerkinElmer Competitors

$137.86
-1.58 (-1.13 %)
(As of 05/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$137.71
$139.87
50-Day Range
$125.20
$140.97
52-Week Range
$88.60
$162.70
Volume669,634 shs
Average Volume995,005 shs
Market Capitalization$15.45 billion
P/E Ratio37.46
Dividend Yield0.20%
Beta1.19

Competitors

PerkinElmer (NYSE:PKI) Vs. TMO, ILMN, A, MTD, WAT, and BIO

Should you be buying PKI stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to PerkinElmer, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), and Bio-Rad Laboratories (BIO).

PerkinElmer (NYSE:PKI) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. PerkinElmer pays out 6.8% of its earnings in the form of a dividend. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. PerkinElmer has increased its dividend for 1 consecutive years and Thermo Fisher Scientific has increased its dividend for 3 consecutive years. Thermo Fisher Scientific is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a breakdown of current ratings for PerkinElmer and Thermo Fisher Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Thermo Fisher Scientific021802.90

PerkinElmer presently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Thermo Fisher Scientific has a consensus target price of $536.8947, indicating a potential upside of 18.06%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than PerkinElmer.

Risk & Volatility

PerkinElmer has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares PerkinElmer and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Thermo Fisher Scientific17.12%21.35%10.55%

Institutional & Insider Ownership

89.4% of PerkinElmer shares are owned by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by company insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares PerkinElmer and Thermo Fisher Scientific's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Thermo Fisher Scientific$25.54 billion7.00$3.70 billion$12.3536.82

Thermo Fisher Scientific has higher revenue and earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats PerkinElmer on 11 of the 17 factors compared between the two stocks.

PerkinElmer (NYSE:PKI) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings for PerkinElmer and Illumina, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Illumina47602.12

PerkinElmer presently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Illumina has a consensus target price of $374.50, indicating a potential upside of 0.45%. Given PerkinElmer's stronger consensus rating and higher probable upside, equities research analysts plainly believe PerkinElmer is more favorable than Illumina.

Risk & Volatility

PerkinElmer has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Profitability

This table compares PerkinElmer and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Illumina19.70%15.93%10.09%

Insider & Institutional Ownership

89.4% of PerkinElmer shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares PerkinElmer and Illumina's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Illumina$3.54 billion15.36$1.00 billion$6.5756.75

Illumina has higher revenue and earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats PerkinElmer on 8 of the 14 factors compared between the two stocks.

PerkinElmer (NYSE:PKI) and Agilent Technologies (NYSE:A) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. PerkinElmer pays out 6.8% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. PerkinElmer has increased its dividend for 1 consecutive years and Agilent Technologies has increased its dividend for 1 consecutive years.

Profitability

This table compares PerkinElmer and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Agilent Technologies13.47%21.02%10.73%

Valuation and Earnings

This table compares PerkinElmer and Agilent Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Agilent Technologies$5.34 billion7.34$719 million$3.2839.22

Agilent Technologies has higher revenue and earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

89.4% of PerkinElmer shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

PerkinElmer has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for PerkinElmer and Agilent Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Agilent Technologies061902.76

PerkinElmer presently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Agilent Technologies has a consensus target price of $107.4350, indicating a potential downside of 16.48%. Given PerkinElmer's stronger consensus rating and higher probable upside, equities research analysts plainly believe PerkinElmer is more favorable than Agilent Technologies.

PerkinElmer (NYSE:PKI) and Mettler-Toledo International (NYSE:MTD) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares PerkinElmer and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Mettler-Toledo International19.36%144.89%21.11%

Valuation and Earnings

This table compares PerkinElmer and Mettler-Toledo International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Mettler-Toledo International$3.01 billion9.60$561.11 million$22.7754.52

Mettler-Toledo International has higher revenue and earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.4% of PerkinElmer shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

PerkinElmer has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for PerkinElmer and Mettler-Toledo International, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Mettler-Toledo International23101.83

PerkinElmer currently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Mettler-Toledo International has a consensus target price of $1,048.3333, indicating a potential downside of 15.56%. Given PerkinElmer's stronger consensus rating and higher probable upside, research analysts clearly believe PerkinElmer is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats PerkinElmer on 10 of the 14 factors compared between the two stocks.

PerkinElmer (NYSE:PKI) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares PerkinElmer and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Waters22.61%-349.31%21.11%

Valuation and Earnings

This table compares PerkinElmer and Waters' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Waters$2.41 billion7.78$592.20 million$8.9933.78

Waters has lower revenue, but higher earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.4% of PerkinElmer shares are owned by institutional investors. Comparatively, 91.8% of Waters shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by insiders. Comparatively, 1.5% of Waters shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

PerkinElmer has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for PerkinElmer and Waters, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Waters37101.82

PerkinElmer currently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Waters has a consensus target price of $251.25, indicating a potential downside of 17.25%. Given PerkinElmer's stronger consensus rating and higher probable upside, research analysts clearly believe PerkinElmer is more favorable than Waters.

Summary

Waters beats PerkinElmer on 8 of the 14 factors compared between the two stocks.

PerkinElmer (NYSE:PKI) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares PerkinElmer and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PerkinElmer12.74%21.57%9.61%
Bio-Rad Laboratories147.91%3.77%2.74%

Valuation and Earnings

This table compares PerkinElmer and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PerkinElmer$2.88 billion5.36$227.56 million$4.1033.62
Bio-Rad Laboratories$2.31 billion7.52$1.76 billion$7.0682.70

Bio-Rad Laboratories has lower revenue, but higher earnings than PerkinElmer. PerkinElmer is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.4% of PerkinElmer shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of PerkinElmer shares are owned by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

PerkinElmer has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for PerkinElmer and Bio-Rad Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PerkinElmer02702.78
Bio-Rad Laboratories00303.00

PerkinElmer currently has a consensus target price of $141.7273, indicating a potential upside of 2.81%. Bio-Rad Laboratories has a consensus target price of $700.00, indicating a potential upside of 19.89%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than PerkinElmer.


PerkinElmer Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$454.78-2.0%$178.74 billion$25.54 billion37.28Insider Selling
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$372.84-2.3%$54.43 billion$3.54 billion86.51
Agilent Technologies logo
A
Agilent Technologies
1.8$128.64-2.2%$39.20 billion$5.34 billion55.93
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,241.45-0.1%$28.89 billion$3.01 billion52.23Earnings Announcement
Waters logo
WAT
Waters
1.3$303.64-4.0%$18.73 billion$2.41 billion37.81Analyst Report
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$583.89-2.1%$17.38 billion$2.31 billion5.00
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.3$316.76-1.2%$15.92 billion$2.62 billion52.79Insider Selling
High Trading Volume
Analyst Revision
Bio-Techne logo
TECH
Bio-Techne
1.8$408.88-1.6%$15.90 billion$738.69 million65.42Earnings Announcement
Dividend Announcement
Bruker logo
BRKR
Bruker
1.7$66.45-4.1%$10.07 billion$2.07 billion65.15Analyst Revision
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$22.93-5.1%$4.55 billion$90.89 million-81.89Gap Down
Luminex logo
LMNX
Luminex
1.5$36.62-0.1%$1.73 billion$334.64 million93.90
Fluidigm logo
FLDM
Fluidigm
1.8$5.18-6.0%$388.31 million$117.24 million-7.73Earnings Announcement
Analyst Report
Gap Down
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.95-0.9%$277.70 million$116.18 million-38.61Earnings Announcement
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.85-0.0%$61.64 million$420,000.00-1.45Analyst Report
News Coverage
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.